

Hepatitis B Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight

Companies working in the market are Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, and Zhimeng Biopharm, and others.

LAS VEGAS, NV, UNITED STATES, December 17, 2024 /EINPresswire.com/ -- DelveInsight's "Hepatitis B Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the Hepatitis B, historical and forecasted epidemiology as well as the Hepatitis B market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Some of the key facts of the [Hepatitis B Market Report](#):

The Hepatitis B market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

In September 2023, Bii Biosciences Limited announced a study of phase 2 clinical trials for PEG-IFN α and BR11-835. This study will evaluate the efficacy and safety of PEG-IFN α alone or in combination with different dose levels of BR11-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.

In September 2023, Gilead Sciences announced a study of phase 1 clinical trials for GS-2829 and GS-6779. The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy participants and participants with CHB.

Key Hepatitis B Companies: Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Asclepis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Bii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, and Zhimeng Biopharm, and others

Key Hepatitis B Therapies: Bevacizumab, HB0025, ST-1898 tablets, Trovax, fruquintinib+sintilimab, Cabozantinib, AMG 102, Pazopanib, tivozanib (AV-951), Belzutifan, Temsirolimus (CCI-779), CB-839, ABT-869, Nivolumab, ABT-510/Thrombospondin-1 mimetic, bevacizumab, CP-461, and others

The Hepatitis B market is expected to surge due to the disease's increasing prevalence and

awareness during the forecast period. Furthermore, launching various multiple-stage Hepatitis B pipeline products will significantly revolutionize the Hepatitis B market dynamics.

Hepatitis B Overview

Hepatitis B is a viral infection that primarily targets the liver and is caused by the Hepatitis B virus (HBV). It represents a significant global health challenge, affecting millions of people worldwide. Hepatitis B can manifest as both an acute and a chronic infection.

Acute Hepatitis B is a short-term infection that lasts less than six months. Many people with acute Hepatitis B experience few or no symptoms, while others may have mild symptoms like fatigue, nausea, and jaundice (yellowing of the skin and eyes). In some cases, acute infection can lead to severe liver damage, liver failure, or even death.

Chronic Hepatitis B is a long-lasting infection, persisting for six months or more. Unlike the acute form, chronic Hepatitis B can last for years, causing ongoing liver inflammation and damage. This prolonged infection increases the risk of serious complications, including cirrhosis (liver scarring), liver cancer, and liver failure. However, not all individuals with chronic Hepatitis B will develop these severe outcomes.

HBV is primarily transmitted through contact with infected blood or body fluids. Common transmission routes include unprotected sexual contact, sharing needles or syringes, and mother-to-child transmission during childbirth. HBV is not spread through casual contact such as hugging, kissing, or sharing food or drinks with an infected person.

Prevention of Hepatitis B is most effectively achieved through vaccination. The Hepatitis B vaccine is safe and highly effective, providing protection against HBV infection. It is recommended for all infants at birth, as well as for individuals at higher risk, including healthcare workers, people with multiple sexual partners, and those who inject drugs.

Treatment for Hepatitis B focuses on reducing liver inflammation, slowing liver damage, and preventing complications. Antiviral medications are commonly prescribed to suppress HBV replication and reduce the risk of liver-related complications in individuals with chronic Hepatitis B.

In summary, Hepatitis B is a serious, but preventable and treatable disease. Increased awareness, widespread vaccination, and improved access to healthcare are essential for controlling HBV transmission and improving outcomes for those affected.

Hepatitis B Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted

epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hepatitis B Epidemiology Segmentation:

The Hepatitis B market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Hepatitis B

Prevalent Cases of Hepatitis B by severity

Gender-specific Prevalence of Hepatitis B

Diagnosed Cases of Episodic and Chronic Hepatitis B

Download the report to understand which factors are driving Hepatitis B epidemiology trends @ [Hepatitis B Epidemiology Forecast](#)

Hepatitis B Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis B market or expected to get launched during the study period. The analysis covers Hepatitis B market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hepatitis B Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hepatitis B Key Companies

Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascleptis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brie Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, and Zhimeng Biopharm

Hepatitis B Therapies

Tenofovir Alafenamidem, VIR-221, Selgantolimod, telbivudine, lamivudine, pegylated interferon-alfa 2a

Hepatitis B Market

The primary treatment for Chronic Hepatitis B currently revolves around antiviral medications, with notable options including entecavir, VEMOLIDY, VIREAD, telbivudine, adefovir dipivoxil, and lamivudine. Lamivudine holds significance as the first nucleoside analogue (NA) to receive approval from the US FDA for Chronic Hepatitis B treatment. Initially approved for adults in 1998, pediatric approval for children aged 2-17 followed in 2001. Despite its initial approval for

Hepatitis B, lamivudine has been utilized and licensed for HIV infection treatment since 1995. While generally well-tolerated with few side effects, prolonged lamivudine therapy is associated with significant rates of drug resistance, leading to virological relapse and biochemical flare. Consequently, lamivudine is often recommended as a second-line therapy for managing Hepatitis B.

To know more about Hepatitis B companies working in the treatment market, visit @ [Hepatitis B Clinical Trials and Therapeutic Assessment](#)

Scope of the Hepatitis B Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Hepatitis B Companies: Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascleris Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Bii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, and Zhimeng Biopharm, and others

Key Hepatitis B Therapies: Tenofovir Alafenamidem, VIR-221, Selgantolimod, telbivudine, lamivudine, pegylated interferon-alfa 2a, and others

Hepatitis B Therapeutic Assessment: Hepatitis B current marketed and Hepatitis B emerging therapies

Hepatitis B Market Dynamics: Hepatitis B market drivers and Hepatitis B market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Hepatitis B Unmet Needs, KOL's views, Analyst's views, Hepatitis B Market Access and Reimbursement

Table of Contents

1. Hepatitis B Market Report Introduction
2. Executive Summary for Hepatitis B
3. SWOT analysis of Hepatitis B
4. Hepatitis B Patient Share (%) Overview at a Glance
5. Hepatitis B Market Overview at a Glance
6. Hepatitis B Disease Background and Overview
7. Hepatitis B Epidemiology and Patient Population
8. Country-Specific Patient Population of Hepatitis B
9. Hepatitis B Current Treatment and Medical Practices
10. Hepatitis B Unmet Needs

11. Hepatitis B Emerging Therapies
12. Hepatitis B Market Outlook
13. Country-Wise Hepatitis B Market Analysis (2019–2032)
14. Hepatitis B Market Access and Reimbursement of Therapies
15. Hepatitis B Market Drivers
16. Hepatitis B Market Barriers
17. Hepatitis B Appendix
18. Hepatitis B Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Hepatitis B Pipeline

"Hepatitis B Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hepatitis B market. A detailed picture of the Hepatitis B pipeline landscape is provided, which includes the disease overview and Hepatitis B treatment guidelines.

Hepatitis B Epidemiology

DelveInsight's 'Hepatitis B Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Hepatitis B epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

Kritika Rehani

DelveInsight Business Research LLP

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/769711559>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.